Beyond Air, Inc (XAIR) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Beyond Air, Inc stock $2.05, price $1.54, upside +33.1%, quality 40 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Beyond Air, Inc
XAIR · USCheap (25% below fair value), but weak company and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $1.54 – $6,244.00 · fair‑value band $1.53 – $3.07 · the $1.54 price screens below the $2.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Beyond Air is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
Show moreShow less
It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions.
It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.
The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Stock analysis
Beyond Air, Inc (XAIR) currently trades at $1.54, while our model-based Fair Value estimate is $2.05, implying the stock looks roughly 25% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.53 (bear) to $3.07 (bull), the price of $1.54 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Beyond Air, Inc reported revenue of $7.7M in FY2026 versus $145K in FY2022, a compound +169.7%/yr. Reported net income was −$33.2M in FY2026.
Key figures
Market cap $2.6M Micro · P/S ratio 0.44 · EPS (TTM) $-60.47 · Return on equity −520% · Return on assets (EBIT) −91.5% (5-year average) · Operating margin −365% · Revenue (TTM) $7.7M · Revenue growth (quarter YoY) +0.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).
What moves the price
The share trades about 96% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 33%, XAIR screens cheaper than that median.
Fair Value models
All 1 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors bought shares worth $224,997, most recently on Jul 29, 2026. Buying cluster
- BuyYi-Chien Lin10% owner2× since Sep 29, 2026: 23,000 shares, avg. $2.71$62,352Oct 13, 2026
- BuyDaniel J MoorheadChief Financial Officer4,340 shares at $5.76$24,998Jul 29, 2026
- BuyRobert Scott GoodmanChief Executive Officer, Director34,722 shares at $5.76$199,999Jul 29, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch XAIR, get fair value alerts →
Compare Beyond Air, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks
Valuation Multiplesvs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Stryker Corporation SYK | $310.00 | $341.00 | +10% | vs XAIR |
| Boston Scientific Corporation BSX | $41.98 | $46.18 | +10% | vs XAIR |
| DexCom, Inc DXCM | $79.32 | $87.25 | +10% | vs XAIR |
| STERIS plc STE | $255.76 | $281.34 | +10% | vs XAIR |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥183.81 | ¥197.34 | +7% | vs XAIR |
| GE HealthCare Technologies Inc GEHC | $80.64 | $69.92 | −13% | vs XAIR |
| Edwards Lifesciences Corporation EW | $101.85 | $81.94 | −20% | vs XAIR |
| Medtronic plc MDT | $99.94 | $74.89 | −25% | vs XAIR |
| Abbott Laboratories, ABT | $103.00 | $75.28 | −27% | vs XAIR |
| Koninklijke Philips N.V PHIA | €26.39 | €15.23 | −42% | vs XAIR |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Beyond Air, Inc (XAIR) overvalued or undervalued?
What is the fair value of XAIR?
What is the quality score of XAIR?
What is the price target for Beyond Air, Inc (XAIR)?
What is the Beyond Air, Inc stock forecast for 2026?
What is the revenue of Beyond Air, Inc (XAIR)?
What is the intrinsic value of Beyond Air, Inc (XAIR)?
Is Beyond Air, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of XAIR?
How much is Beyond Air, Inc worth?
What do the bullish and bearish scenarios say about XAIR?
How solid is the balance sheet of Beyond Air, Inc (XAIR)?
How far is XAIR from its 52-week high?
Which stocks are comparable to Beyond Air, Inc?
Is Beyond Air, Inc stock attractive at the current price?
How is the fair value of XAIR calculated?
Is it still worth investing in stocks now?
What is the share price of Beyond Air, Inc (XAIR)?
What should I pay attention to with Beyond Air, Inc right now?
Key figures of Beyond Air, Inc
How large is the market capitalisation of Beyond Air, Inc (XAIR)?
What is the P/S ratio of Beyond Air, Inc (XAIR)?
What are the earnings per share of Beyond Air, Inc (XAIR)?
What is the return on equity of Beyond Air, Inc (XAIR)?
What is the EBIT return on assets of Beyond Air, Inc (XAIR)?
What is the operating margin of Beyond Air, Inc (XAIR)?
How fast is revenue growing at Beyond Air, Inc (XAIR)?
How much free cash flow does Beyond Air, Inc (XAIR) generate?
How much net debt does Beyond Air, Inc (XAIR) carry?
Watch Beyond Air, Inc in the live analysis
One click puts Beyond Air, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.